BioNTech said in a regulatory filing on Tuesday the U.S. Food and Drug Administration has placed a clinical hold on an ...

BioNTech SE (NASDAQ:BNTX) said on Tuesday, that the U.S. Food and Drug Administration informed of a clinical hold on the ...

In a regulatory filing, BioNTech (BNTX) disclosed that the U.S. Food and Drug Administration has informed BioNTech SE that it has placed a ...

The current COVID-19 vaccine is 33% effective at preventing emergency department or urgent care visits among adults of all ages. It also is 45% to 46% effective at preventing hospitalizations in older ...

We recently published a list of the 10 Best Vaccine Stocks to Buy According to Hedge Funds. In this article, we are going to ...

The FDA’s clinical hold has prompted a cautious response from investors, reflecting the heightened regulatory scrutiny that BioNTech now faces. The company’s immediate focus will be on resolving the ...

Late last week in Morbidity and Mortality Weekly Report, authors from the Centers for Disease Control and Prevention (CDC) ...

A clinical trial from Memorial Sloan Kettering Cancer Center looked at the effects of a targeted mRNA vaccine on early-stage ...

Researchers associated with the New York-based Memorial Sloan Kettering Cancer Center have obtained positive results in the ...

Stocks of MRNA, PFE, NVAX and BNTX rose in anticipation that a new virus in China could trigger another pandemic.

Ugur Sahin, the co-founder and CEO of BioNTech SE (BNTX), sold $119.58 million worth of the Germany-based biotechnology ...